argument5超越自我小组第六次作业

zugurrrUID: 2482827

The arguer conclude that as the pharmaceu tical companies producing drugs for arthritis will be very profitable over next twenty years, Perkins Pharmaceuticals will be the most Profictable pharmaceutiacal company, which produce new drug Xylan preferred over Xenon as the best-selling drug for arthritis by Becton Pharmaceuticals. However, there are several fallacies about the statement.

First, if other new drugs produced from Bceton is much better than Xylan, the most profitable company should not be Perkins, because for ten years, having the producing technology of Xenon so long time, Bceton have the more advantages than Xylan in the research of new drug for arthritis. On the other hand, if the clinical studies are confined to the small number patients, or during the short time, then we have reasons to doubt the worthiness of the data. Because most drugs have spent a long time for its validity and the potential risks. Moreover, the profits of a pharmaceutical company should not only depend on one drug. If the other drugs could not earn money for the company, or most of them just prove wasting investments, then even though this drug is profitable, the companies maybe remain unprofitable.

Second, if the people suffering from arthritis have more choices for their treatment, instead of the only drugs of Xenon and Xylan. Ten years is a long time for the development of the drug market where there may be more other more effective and cheap drugs, or maybe more patients chose the other treatments like operation.

Third, number of the data is about general whole country, but if the main market of these two pharmaceutical companies is oversea or some parts of the country where the number of patients suffering from arthritis is decrease rather than the general tendency of increase, then how do these two companies gain the money? And the arguer fails to provide information about other drugs for arthritis from the other companies. If in the market where the supply for the drugs of arthritis is much over the demand, the data would mislead the readers and the drugs may hardly be sold as many as predict.

In sum, the arguer fails to provide the evidence that in the next ten years, the new drug from Perkins would be the most-selling drug. To strengthen the conclusion, there should be the information to support that the need of Xylan from people suffering from arthritis would be increase more than the Becton or other possible new drugs from Bection. And the market for most Perkins' drug would extend and make sure the profits from majority of their drugs.

vryUID: 2288609

The arguer conclude that as the pharmaceu tical companies producing drugs for arthritis will be very profitable over next twenty years, Perkins Pharmaceuticals will be the most Profictable pharmaceutiacal company, which produce new drug Xylan preferred over Xenon as the best-selling drug for arthritis by Becton Pharmaceuticals. However, there are several fallacies about the statement.

First, if other new drugs produced from Bceton is much better than Xylan, the most profitable company should not be Perkins, because for ten years, having the producing technology of Xenon so long time, Bceton have the more advantages than Xylan in the research of new drug for arthritis. On the other hand, if the clinical studies are confined to the small number patients, or during the short time, then we have reasons to doubt the worthiness of the data. Because most drugs have spent a long time for its validity and the potential risks. Moreover, the profits of a pharmaceutical company should not only depend on one drug. If the other drugs could not earn money for the company, or most of them just prove wasting investments, then even though this drug is profitable, the companies maybe remain unprofitable.

Second, if the people suffering from arthritis have more choices for their treatment, instead of the only drugs of Xenon and Xylan. Ten years is a long time for the development of the drug market where there may be more other more effective and cheap drugs, or maybe more patients chose the other treatments like operation.

Third, number of the data （什么数据？最好再指出）is about general whole country, but if the main market of these two pharmaceutical companies is oversea or some parts of the country where the number of patients suffering from arthritis is decrease rather than the general tendency of increase, then how do these two companies gain the money? And the arguer fails to provide information about other drugs for arthritis from the other companies. If in the market where the supply for the drugs of arthritis is much over the demand, the data would mislead the readers and the drugs may hardly be sold as many as predict.

In sum, the arguer fails to provide the evidence that in the next ten years, the new drug from Perkins would be the most-selling drug.(前面分析了吆喝公司利润的关系，怎么这里又变成这样了)  To strengthen the conclusion, there should be the information to support that the need of Xylan from people suffering from arthritis would be（be去掉） increase more than the Becton or other possible new drugs from Bection. And the market for most Perkins' drug would extend and make sure the profits from majority of their drugs.

1本文缺少了对 “But the patent on Xenon expires in three years, and other companies will then be able to produce a cheaper version of the drug.”的攻击
2整体感觉很好~~~ 加油加油~~~